WASHINGTON — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug rebate rule, while calling for a complete Congressional repeal.
“We applaud the Biden Administration for delaying the rebate rule’s effective date in order to further examine the rule’s impact on Medicare beneficiaries,” said JC Scott, president and CEO of PCMA. “There is no question that the rebate rule would significantly raise premiums in Medicare Part D while increasing the program’s costs to taxpayers. As long as this rule remains in place, there will be uncertainty and risk for seniors. It’s time to close the book on the rebate rule and begin working on real solutions to lower drug price prices and out-of-pocket costs in Medicare and for all patients.”
As part of the launch of the campaign, PCMA released:
- A series of news ads;
- An interactive map outlining the rebate rule’s state-by-state 10-year premium increase; and
- A new podcast on the rule and its potential impact.
Click here to view the ads, map, and other materials.